2. Signaling Pathways
  3. Immunology/Inflammation
  4. Complement System
  5. Complement System Antagonist

Complement System Antagonist

Complement System Antagonists (15):

Cat. No. Product Name Effect Purity
  • HY-101502A
    SB290157 trifluoroacetate
    		Antagonist 99.87%
    SB290157 trifluoroacetate is a potent and selective C3a receptor antagonist with an IC50 of 200 nM.
  • HY-106178
    PMX-53
    		Antagonist 99.98%
    PMX-53 (3D53) is a synthetic peptidic and a potent and orally active complement C5a receptor (CD88) antagonist with an IC50 of 20 nM. PMX-53 is also a low-affinity MrgX2 agonist that stimulates MrgX2-mediated mast cell degranulation. PMX-53 specifically binds to C5aR1 and does not bind to the second C5aR (C5L2) and C3aR. PMX-53 has anti-inflammatory, anticancer and antiatherosclerotic effects.
  • HY-10799
    EG00229 trifluoroacetate
    		Antagonist 98.18%
    EG00229 is a neuropilin 1 (NRP1) receptor antagonist. EG00229 selectively inhibits VEGF-A binding to NRP1 b1 domain with an IC50 of 3 μM, but has no effect on VEGFA binding to VEGFR-1 and VEGFR-2.
  • HY-138161
    JR14a
    		Antagonist 99.59%
    JR14a is a potent thiophene antagonist of human complement C3a receptor. JR14a shows selectivity for the human C3a receptor over C5a receptor. JR14a can suppress C3aR-mediated inflammation.
  • HY-110136A
    PMX 205 Trifluoroacetate
    		Antagonist 99.50%
    PMX 205 Trifluoroacetate is a specific complement C5aR1 isoform antagonist.
  • HY-148141
    JPE-1375
    		Antagonist 99.94%
    JPE-1375 is a complement C5a receptor 1 (C5aR1) antagonist. JPE-1375 effectively inhibits polymorphonuclear leukocyte mobilization (EC50=6.9 µM) and reduces TNF levels (EC50=4.5 µM) in mice. JPE-1375 can be used in studies of autoimmune and inflammatory diseases.
  • HY-16992A
    W-54011
    		Antagonist ≥98.0%
    W-54011 is a potent and orally active non-peptide C5a receptor antagonist. W-54011 inhibits the binding of 125I-labeled C5a to human neutrophils with a Ki value of 2.2 nM. W-54011 also inhibits C5a-induced intracellular Ca2+ mobilization, chemotaxis, and generation of ROS in human neutrophils with IC50s of 3.1 nM, 2.7 nM, and 1.6 nM, respectively.
  • HY-133034
    NRP1 antagonist 1
    		Antagonist 99.80%
    NRP1 antagonist 1 (compound 12a) is a potent NRP1 antagonist with an IC50 of 19.1 μM. NRP1 antagonist 1 has the potential for cancer research.
  • HY-110060
    NDT 9513727
    		Antagonist 99.35%
    NDT 9513727 is a potent, selective, orally active and competitive inverse agonist of the human C5aR (C5a receptor), with an IC50 of 11.6 nM. NDT 9513727 can be used for the research of human inflammatory diseases.
  • HY-147762
    NRP1 antagonist 2
    		Antagonist 99.05%
    NRP1 antagonist 2 (Compound 1) is an NRP1 antagonist.
  • HY-112199
    CP-447697
    		Antagonist 99.70%
    CP-447697 is a lipophilic C5a receptor antagonist with an IC50 value of 31 nM. CP-447697 can be used for the research of inflammation.
  • HY-110136
    PMX 205
    		Antagonist
    PMX 205 is a potent complement C5a receptor (C5aR; CD88) antagonist.
  • HY-163378
    C5aR1 antagonist 1
    		Antagonist
    C5aR1 antagonist 1 (Compound 7e) is an orally active C5a receptor 1 (C5aR1) antagonist. C5aR1 antagonist 1 is active in DISCO and migration assays, with IC50 values of 38 nM and 17 nM, respectively. C5aR1 antagonist 1 can be used for the research of acute and chronic inflammatory diseases.
  • HY-16384
    L-156602
    		Antagonist
    L-156602 is a C5a receptor antagonist. L-156602 inhibits inflammation, and the migration of monocytes and neutrophils to the infiltrating site in mouse inflammatory models. L-156602 suppresses the efferent phase of delayed-type hypersensitivity (DTH).
  • HY-163379
    C5aR1 antagonist 2
    		Antagonist
    C5aR1 antagonist 2 (Compound 6a) is an orally active C5a receptor 1 (C5aR1) antagonist that shows efficacy in inhibiting the C5a-induced neutrophil count increase. C5aR1 antagonist 2 is potent in the DISCO and migration assays, with IC50 values of 21 and 3 nM, respectively. C5aR1 antagonist 2 can be used for the research of acute and chronic inflammatory diseases.